Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
about
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.Prevention of Carcinogen-Induced Oral Cancer by SulforaphaneSecond-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.Investigational drugs for head and neck cancer.Positioning of proteasome inhibitors in therapy of solid malignancies.Cancer metabolism: New insights into classic characteristics.
P2860
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Carfilzomib and oprozomib syne ...... ance to proteasome inhibitors.
@en
type
label
Carfilzomib and oprozomib syne ...... ance to proteasome inhibitors.
@en
prefLabel
Carfilzomib and oprozomib syne ...... ance to proteasome inhibitors.
@en
P2093
P2860
P356
P1476
Carfilzomib and oprozomib syne ...... ance to proteasome inhibitors.
@en
P2093
Christopher J Kirk
Daniel E Johnson
P2860
P304
P356
10.4161/CBT.29452
P577
2014-06-10T00:00:00Z